Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with
Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see
what effects (good and bad) it has on you and on your cancer.